Bloomberg Law
April 14, 2021, 9:26 PM

NIH Closes Enrollment in Trial Comparing Covid-19 Treatments

Linly Lin
Linly Lin
Bloomberg News

The NIAID-sponsored trial aimed to determine which of two drug combinations—baricitinib plus remdesivir or dexamethasone plus remdesivir—was more effective.

  • Enrollment has closed because the study met pre-defined futility criteria indicating that neither treatment regimen studied is likely significantly better than the other
  • Remdesivir is developed by Gilead Sciences; Baricitinib is discovered by Incyte and licensed to Eli Lilly; Dexamethasone is a generic drug

To contact the reporter on this story:
Linly Lin in San Francisco at

To contact the editor responsible for this story:
Chakradhar Adusumilli at

© 2021 Bloomberg L.P. All rights reserved. Used with permission.